Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma

NCT01959139 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT01959139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01959139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 1/2
Overall status
Completed
Start date
January 23, 2014
Completion date
November 9, 2023
Enrollment
126 (actual)
Sites
154

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma